Antibiotic Therapy and 48-Hour Mortality for Patients with Pneumonia
|
|
- Jeffry Waters
- 5 years ago
- Views:
Transcription
1 The American Journal of Medicine (2006) 119, CLINICAL RESEARCH STUDY AJM Theme Issue: Pulmonology/Allergy Antibiotic Therapy and 48-Hour Mortality for Patients with Pneumonia Eric M. Mortensen, MD, MSc, a,b Marcos I. Restrepo, MD, MSc, a,c Antonio Anzueto, MD, c Jacqueline A. Pugh, MD a,b a Veterans Evidence Based Research Dissemination and Implementation Center, and Divisions of b General Internal Medicine and c Pulmonary/Critical Care Medicine, South Texas Veterans Health Care System, San Antonio, Tex. ABSTRACT PURPOSE: Although numerous articles have demonstrated that recommended empiric antimicrobial regimens are associated with decreased mortality at 30 days, there is controversy over whether appropriate antibiotic selection has a beneficial impact on mortality within the first 48 to 96 hours after admission. Our aim was to determine whether the use of guideline-concordant antibiotic therapy is associated with decreased mortality within the first 48 hours after admission for patients with pneumonia. METHODS: A retrospective cohort study was conducted at two tertiary teaching hospitals in San Antonio, Texas. A propensity score was used to balance the covariates associated with the use of guideline-concordant antimicrobial therapy. A multivariable logistic regression model was used to assess the association between mortality within 48 hours and the use of guideline-concordant antibiotic therapy, after adjusting for potential confounders including the propensity score. RESULTS: Information was obtained on 787 patients with community-acquired pneumonia. The median age was 60 years, 79% were male, and 20% were initially admitted to the intensive care unit. At presentation 52% of subjects were low risk, 34% were moderate risk, and 14% were high risk. Within the first 48 hours, 20 patients died. After adjustment for potential confounders, the use of guideline-concordant antimicrobial therapy (odds ratio 0.37, 95% confidence interval, ) was significantly associated with decreased mortality at 48 hours after admission. CONCLUSION: Using initial empiric guideline-concordant antimicrobial therapy is associated with decreased mortality at 48 hours. Further research needs to investigate methods to ensure that patients with community-acquired pneumonia are treated with appropriate antimicrobial therapies Elsevier Inc. All rights reserved. KEYWORDS: Antibacterial agents; Community-acquired infections; Pneumonia Dr. Mortensen was supported by a Department of Veteran Affairs Vertically Integrated Service Network 17 new faculty grant and a Howard Hughes Medical Institute faculty start-up grant Dr. Pugh was supported by Department of Veteran Affairs grants REA and RCD This material is the result of work supported with resources and the use of facilities at the South Texas Veterans Health Care System. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. Manuscript submitted on September 27, 2005, and accepted in revised form on April 5, Requests for reprints should be addressed to Eric Mortensen, MD, MSc, VERDICT, ALMD/UTHSCSA, Ambulatory Care (11C6), 7400 Merton Minter Boulevard, San Antonio, TX address: mortensene@uthscsa.edu. The data suggest that antimicrobial therapy has little or no effect upon the outcome of infection among those destined at the onset of illness, to die within 5 days. Robert Austrian and Jerome Gold, Community-acquired pneumonia is the seventh leading cause of death in the United States and is the leading infectious cause of death. 22 Although mortality decreased precipitously with the advent of antimicrobial therapy, since 1950 mortality has been stable or gradually increased. 3 Because of this substantial mortality, numerous professional societies including the American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA), British Thoracic Society, and others have published clinical practice guidelines for community-acquired pneumonia /$ -see front matter 2006 Elsevier Inc. All rights reserved. doi: /j.amjmed
2 860 The American Journal of Medicine, Vol 119, No 10, October 2006 Although there is considerable evidence that the use of empiric guideline-concordant antimicrobials is associated with improved survival at 30 days, controversy still exists about whether the use of antibiotics has an impact on survival in the first 48 to 96 hours after admission. 1,16 In addition, randomized clinical trials of antibiotics for communityacquired pneumonia frequently exclude patients who are expected to die within the first 48 to 72 hours because of the concern that these patients will die no matter what antimicrobial therapy they receive. 17 Our aim was to determine whether the use of guideline-concordant antibiotic therapy is associated with decreased mortality within the first 48 hours after admission for patients with community-acquired pneumonia. CLINICAL SIGNIFICANCE METHODS This was a retrospective cohort study of patients hospitalized with community-acquired pneumonia at two academic tertiary care hospitals in San Antonio, Texas. Both hospitals are teaching affiliates of the University of Texas Health Science Center at San Antonio. The Institutional Review Board of the University of Texas Health Science Center at San Antonio approved the research protocol with exempt status. Study Sites/Inclusion and Exclusion Criteria We identified all patients admitted to the study hospitals between January 1, 1999, and December 1, 2002, with a primary discharge diagnosis of pneumonia (International Classification of Diseases-Ninth Revision codes or ) or secondary discharge diagnosis of pneumonia with a primary diagnosis of respiratory failure (518.81) or sepsis (038.xx). Subjects were included if they were aged more than 18 years, had an admission diagnosis of community-acquired pneumonia, and had a radiographically confirmed infiltrate or other finding consistent with community-acquired pneumonia on chest x-ray or computed tomography obtained within 24 hours of admission. Exclusion criteria included discharge from an acute care facility within 14 days of admission, transfer after being admitted to another acute care hospital, and receiving comfort measures only on this admission. If a subject was admitted more than once during the study period, only the first hospitalization was abstracted. Data Abstraction Chart review data included demographics, comorbid conditions, physical examination findings, laboratory data, and chest radiograph reports. In addition, data on important processes of care measures for patients hospitalized with community-acquired pneumonia also were abstracted: first Pneumonia is the leading infectious cause of death in the United States. Prompt antibiotic therapy consistent with national practice pneumonia guidelines is associated with decreased mortality at 48 hours after admission. dose of antibiotics within 4 hours of admission, collection of blood cultures before antibiotic administration and in the first 24 hours, and oxygen saturation measurement within 24 hours of presentation. 18 Mortality was assessed using information from the Texas Department of Health and the Department of Veteran Affairs clinical database. Mortality status was assessed through December 31, Antimicrobial Therapy We obtained information on antimicrobial therapy given within the first 48 hours of admission. Antimicrobial therapy was considered guideline-concordant if it agreed with either the 2003 IDSA or 2001 ATS clinical practice guidelines. 7,19 Therapies considered to be guideline-concordant for patients on the medical wards included a beta-lactam with doxycycline or a macrolide, or an antipneumococcal fluoroquinolone alone. Regimens considered guideline-concordant for patients hospitalized in the intensive care unit (ICU) included a beta-lactam with a macrolide or antipneumococcal fluoroquinolone, antipseudomonal beta-lactam aminoglycoside macrolide, or an antipneumococcal fluoroquinolone with clindamycin, vancomycin, or an aminoglycoside (for penicillin-allergic patients). Guideline-appropriate beta-lactam antibiotics included ceftriaxone, cefotaxime, cefepime, ampicillinsulbactam, ampicillin (high dose), piperacillin-tazobactam, imipenem-cilastatin, and meropenem. Guideline-appropriate fluoroquinolones included levofloxacin, gatifloxacin, and moxifloxacin. Appropriate macrolides included erythromycin, clarithromycin, and azithromycin. For a therapy to be considered guideline-concordant, the patient must have received at least one dose of each component of the recommended combinations within the first 48 hours of admission. Risk Adjustment The pneumonia severity index was used to assess severity of illness at presentation. 20 The pneumonia severity index is a validated prediction rule for 30-day mortality in patients with community-acquired pneumonia. This rule is based on 3 demographic characteristics, 5 comorbid illnesses, 5 physical examination findings, and 7 laboratory and radiographic findings from the time of presentation. Patients are classified into 5 risk classes with 30-day mortality ranging from 0.1% for class I to 27% for class V for patients enrolled in the Pneumonia Patient Outcomes Research Team cohort study. 20 Statistical Analyses Univariate statistics were used to test the association of sociodemographic and clinical characteristics with all-cause mortality at 48 hours. Categoric variables were analyzed
3 Mortensen et al 48-Hour Mortality in Pneumonia 861 Table 1 Subject Demographic and Clinical Characteristics by Mortality at 48 Hours* 48-hour mortality Variable Alive (n 767) Dead (n 20) P value Age, years standard deviation Men 603 (79) 18 (90).2 Nursing home resident 49 (6) 5 (25).001 Received antibiotics before admission 135 (18) 5 (25).4 Admitted through emergency department 640 (83) 16 (80).7 Admitted to intensive care within 24 h 142 (18) 12 (60).001 Mechanical ventilation 77 (9) 11 (55).001 Preexisting comorbid conditions Congestive heart failure 117 (15) 6 (30).07 Chronic pulmonary disease 211 (28) 7 (35).5 History of stroke 100 (13) 5 (25).12 Chronic liver disease 92 (12) 2 (10).8 History of malignancy 75 (10) 3 (15).4 Renal insufficiency 83 (11) 4 (20).2 History, physical, laboratory, and radiographic data Altered mental status 76 (10) 9 (45).001 Respiratory rate 30 breaths/min 80 (10) 2 (10).9 Systolic blood pressure 90 mm Hg 18 (2) 3 (15).001 Heart rate 125 beats/min 99 (13) 6 (30).03 Temperature 95 or (3) 1 (5).5 Arterial ph (6) 5 (25).001 Arterial oxygenation saturation 90% 167 (22) 9 (45).01 Hematocrit 30% 69 (9) 3 (15).4 Serum blood urea nitrogen 30 mg/dl 160 (21) 8 (40).04 Serum glucose 250 mg/dl 74 (10) 2 (10) 1.0 Serum sodium 130 meq/l 111 (15) 5 (25).2 Pleural effusion on chest radiograph 184 (24) 5 (25).9 Multilobar infiltrates 264 (35) 8 (40).6 Pneumonia Severity Index Class I-III 406 (53) 3 (15) Class IV 255 (33) 11 (55) Class V 106 (14) 6 (30).003 *Data are presented as number (%) or mean standard deviation. using the chi-square test, and continuous variables were analyzed using the Student t test. A propensity score technique was used to balance covariates associated with antimicrobial therapy between groups The propensity score was derived from a logistic regression model. The covariates included in the propensity score model were the pneumonia severity index, admission through the emergency department, ICU admission within 24 hours, receiving initial antibiotics within 4 hours, having positive blood cultures, and hospital assignment. We then created an ordered categoric variable based on a quartile stratification of the propensity score to include in the Cox and regression models. Stratifying by the propensity score there was not a significant difference between the dead versus live at 48 hours for patients who were hospitalized in the ICU (P.7) or medicine wards (P.2). We used a Cox proportional hazard model to estimate and graph the baseline survivor functions after adjusting for the propensity score. We used logistic regression to assess the impact of empiric antimicrobial therapy on mortality at 48 hours. A dichotomous indicator variable indexing whether a patient received a guideline-concordant therapy was our predictor variable. Covariates included in the model were the use/ non-use of guideline-concordant antimicrobial therapy, and the ordered categoric variable based on quartile stratification on the propensity score. Model fit was assessed using the Hosmer-Lemeshow goodness-of-fit test. 24 All analyses were performed using STATA version 8 (Stata Corporation, College Station, Tex). RESULTS Data were abstracted on 787 patients at the 2 hospitals. The mean age was 60 years with a standard deviation of 16 years. Of the population, 79% were male, 84% were admitted through the emergency department, and 20% were admitted to the ICU within the first 24 hours after admission. Mortality was 2.5% at 48 hours, 9.2% at 30 days, and 13.6% at 90 days. By pneumonia severity index, 52% were low risk (pneumonia severity index classes I-III), 34% were moderate risk (pneumonia severity index class IV), and 14%
4 862 The American Journal of Medicine, Vol 119, No 10, October 2006 Table 2 Subject Demographic and Clinical Characteristics by Use of Guideline-Concordant versus Non Guideline-Concordant Antibiotics* Variable Antimicrobial regimen Concordant (n 625) Nonconcordant (n 162) P value Age, years standard deviation Men 473 (76) 148 (91).0001 Nursing home resident 37 (6) 17 (11).04 Received antibiotics before admission 111 (18) 29 (18).9 Admitted through emergency department 527(84) 129 (80).2 Admitted to intensive care within 24 h 106 (17) 48 (30).0001 Mechanical ventilation 70 (11) 18 (11).9 Preexisting comorbid conditions Congestive heart failure 90 (14) 33 (20).06 Chronic pulmonary disease 162 (26) 56 (35).03 History of stroke 75 (12) 30 (19).03 Chronic liver disease 77 (12) 17 (10).5 History of malignancy 50 (8) 28 (18).001 Renal insufficiency 66 (11) 21 (13).4 History, physical, laboratory, and radiographic data Altered mental status 61 (10) 24 (15).07 Respiratory rate 30 breaths/min Systolic blood pressure 90 mm Hg 13 (2) 8 (5).04 Heart rate 125 beats/min 90 (14) 15 (9).09 Temperature 95 or (3) 3 (2).5 Arterial ph (7) 6 (4).14 Arterial oxygenation saturation 90% 140 (22) 36 (22).9 Hematocrit 30% 49 (8) 23 (14).01 Serum blood urea nitrogen 30 mg/dl 131 (21) 37 (23).6 Serum glucose 250 mg/dl 61 (10) 15 (9).8 Serum sodium 130 meq/l 93 (15) 23 (14.2).8 Pleural effusion on chest radiograph 150 (24) 39 (25).9 Multilobar infiltrates 226 (36) 46 (29).07 Pneumonia Severity Index Class I-III 347 (55) 62 (38) Class IV 194 (31) 72 (44) Class V 84 (13) 28 (18).0001 *Data are presented as number (%) or mean standard deviation. were high risk (pneumonia severity index class V). In regard to pneumonia-related processes of care, 28% of patients received the initial dose of antibiotics within 4 hours of presentation, 76% of patients had blood cultures obtained within 24 hours and before antibiotics, and 91% of patients had oxygenation assessed at presentation. Table 1 shows the demographic factors and clinical characteristics for this population by mortality at 48 hours. In the univariate analysis, variables significantly associated with mortality at 48 hours (P.05) included living in a nursing home, admission to the ICU within 24 hours, need for mechanical ventilation, altered mental status on presentation, arterial hypoxia, and arterial ph 7.35 or less. In addition, increasing pneumonia severity index risk class was associated with increased mortality at 48 hours. Of the patients hospitalized in the ICU, 12 of 20 died within 48 hours, and 70% of patients who were in the ICU received guideline-concordant antibiotics. Of patients who died within 48 hours, 67% of patients in the ICU received guideline-concordant antibiotics. There were no significant differences between the mortality rates for patients in the ICU who received guideline-concordant therapy versus non guideline-concordant (67% vs 69%, P.9). Table 2 shows the demographics, comorbid conditions, and clinical characteristics by whether or not a patient received guideline-concordant therapy. Variables significantly associated with the use of guideline-concordant therapy included admission to the ward, no history of chronic pulmonary disease, no history of stroke, no history of malignancy, hematocrit greater than 30%, and systolic blood pressure greater than 90 mm Hg. All variables with significant associations with the use of guideline-concordant therapy were included as part of the propensity score. There were 63 patients with positive blood cultures (excluding those patients who had only one blood culture positive for coagulase-negative Staphylococcus). The most frequently isolated organism by blood culture was Streptococcus pneumoniae in 34 patients (54%).
5 Mortensen et al 48-Hour Mortality in Pneumonia Guideline-Concordant Antibiotics, n= Non-Guideline Concordant Antibiotics, n= Days Figure 1 Proportion of surviving patients hospitalized with community-acquired pneumonia by use of guideline-concordant antibiotics versus non guideline-concordant antibiotics after adjusting for the propensity score (P.05). The initial empiric antimicrobial therapy was guidelineconcordant in 79.4% of patients: 82% (519/633) of ward patients and 69% (106/154) of ICU patients. Of patients who died within 48 hours, 67% of ICU patients received guideline-concordant antibiotics compared with 38% of ward patients. The most common appropriately prescribed empiric antimicrobial regimens included the use of a betalactam and macrolide (n 156), a beta-lactam and fluoroquinolone (n 126), a beta-lactam fluoroquinolone macrolide (n 125), or an antipneumococcal fluoroquinolone only in ward patients (n 200). The most common non guideline-concordant antimicrobial regimen was the use of a beta-lactam alone (n 97), which was received by 35% (7/20) of patients who died within 48 hours compared with 12% (90/767) who survived that time period (P.002). Figure 1 demonstrates the results of the survival analysis after adjusting for the propensity score. It demonstrates statistically significant difference in survival starting at the first day after admission for those who received guidelineconcordant antibiotics versus non guideline-concordant antibiotics (P.05). At 7 days after hospital admission there was a 2.7% difference in survival. In the regression analysis, after adjusting for potential confounders using the propensity score, use of guidelineconcordant antibiotics was associated with decreased mortality at 48 hours (odds ratio 0.37; 95% confidence interval [CI], , P.04). DISCUSSION Community-acquired pneumonia continues to be an acute medical problem with substantial mortality and morbidity. 2 Our study calls into question the concept that mortality within the first 48 to 96 hours after admission is not modifiable, and provides further evidence for the beneficial effect of the use of the empiric antimicrobial regimens recommended by the IDSA/ATS guidelines. Our results strengthen the previous body of research addressing what antimicrobial therapies are appropriate for patients with community-acquired pneumonia. Previous studies have found that the use of a beta-lactam plus a macrolide is associated with significantly lower mortality These studies demonstrated that monotherapy with beta-lactam is associated with worse outcomes including increased mortality or increased length of stay ,25 Several other studies demonstrated that the use of empiric antimicrobial therapy concordant with national guidelines is associated with decreased mortality. 13,15,26 All of these studies examined in-hospital, or 30-day mortality, and did not examine the impact of antimicrobial therapy on mortality within the first 48 to 96 hours. To our knowledge, our study is one of the only studies to examine early mortality for patients with community-acquired pneumonia since the ground-breaking article by Austrian and Gold. 1 These results also call into question the research practice of excluding patients who physicians believe may not survive the first 48 to 72 hours from randomized clinical trials
6 864 The American Journal of Medicine, Vol 119, No 10, October 2006 of antibiotic therapy. These patients may have the most to benefit from these trials, especially because the control groups frequently receive guideline-concordant antibiotic combinations. 17 If patients at high risk of 48- to 72-hour mortality are included in antibiotic trials, one would expect that the mortality rates reported by randomized controlled trials may be closer to the rates reported in observational studies of community-acquired pneumonia. 27 Our study has several limitations that should be acknowledged. First, our sample was predominantly male because of the inclusion of a Veterans Affairs hospital, and it is possible, but unlikely, that females may have differential responsiveness to antibiotics from males. Also, because of the study design there were a number of variables associated with use versus non-use of guideline-concordant therapy. We used the propensity score to adjust for these differences; however, there is the potential that we were not able to fully adjust for these differences or other unmeasured differences. Finally, there were only a small number of deaths within 48 hours in this cohort so we are unable to fully explore other potential predictors of death or the impact of specific antimicrobial therapies on mortality. CONCLUSION This study demonstrates that receiving guideline-concordant antimicrobial therapy is associated with lower 48-hour mortality for patients hospitalized with community-acquired pneumonia. This finding provides further support for the use of empiric antimicrobial therapies consistent with guidelines from the IDSA and ATS. 7,19 Further research is needed to determine how to promote the use of guidelineconcordant antimicrobial regimens for patients hospitalized with community-acquired pneumonia. References 1. Austrian R, Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann Intern Med. 1964;60: Freid VM, Prager K, MacKay AP, Xia H. Health, United States, 2003 with Chartbook on Trends in the Health of Americans. Hyattsville, MD: National Center for Health Statistics; Gilbert K, Fine MJ. Assessing prognosis and predicting patient outcomes in community-acquired pneumonia. Semin Respir Infect. 1994; 9(3): Society BT. Guidelines for the management of community-acquired pneumonia in adults admitted to the hospital. Br J Hosp Med. 1993; 49(5): Gialdroni Grassi G, Bianchi L. Guidelines for the management of community-acquired pneumonia in adults. Italian Society of Pneumology. Italian Society of Respiratory Medicine. Italian Society of Chemotherapy. Monaldi Arch Chest Dis. 1995;50(1): Niederman M, Bass JB, Campbell GD, et al. Guidelines for the initial management of adult with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis. 1993;148: Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163(7): Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 2000;31(2): British Thoracic Society guidelines for the management of community acquired pneumonia in adults. Thorax. 2001;56(Suppl 4):IV Mandell LA, Marrie TJ, Grossman RF, et al. Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can Respir J. 2000;7(5): Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 1999; 159(21): Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 Western States: 1993, 1995, and Chest. 2001;119: Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia. Arch Intern Med. 2002; 162: Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med. 2001;161(15): Mortensen EM, Restrepo M, Anzueto A, Pugh J. Effects of guidelineconcordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med. 2004;117(10): Wunderink RG, Waterer GW. Community-acquired pneumonia: pathophysiology and host factors with focus on possible new approaches to management of lower respiratory tract infections. Infect Dis Clin North Am. 2004;18(4): , vii. 17. Marrie T. Community-acquired Pneumonia. New York, NY: Kluwer Academic; Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997; 278(23): Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003;37(11): Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4): Stone RA, Obrosky DS, Singer DE, Kapoor WN, Fine MJ. Propensity score adjustment for pretreatment differences between hospitalized and ambulatory patients with community-acquired pneumonia. Pneumonia Patient Outcomes Research Team (PORT) Investigators. Med Care. 1995;33(4 Suppl):AS56-AS Klungel OH, Martens EP, Psaty BM, et al. Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol. 2004;57(12): Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70: Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley and sons; 1989 (Wiley series in probability and mathematical statistics). 25. Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest. 2003;123: Malone DC, Shaban HM. Adherence to ATS guidelines for hospitalized patients with community-acquired pneumonia. Ann Pharmacother. 2001;35: Shefet D, Robenshtok E, Leibovici L. Empirical atypical coverage for inpatients with community-acquired pneumonia. Arch Intern Med. 2005;165:
Measure Information Form
Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form
Last Updated: Version 3.2a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Organization Set Measure ID#
More informationInitial Antibiotic Selection and Patient Outcomes: Observations from the National Pneumonia Project
SUPPLEMENT ARTICLE Initial Antibiotic Selection and Patient Outcomes: Observations from the National Pneumonia Project Dale W. Bratzler, Allen Ma, and Wato Nsa Oklahoma Foundation for Medical Quality,
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Voluntary Only
Last Updated: Version 4.4a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Collected For: CMS Voluntary
More informationControl emergence of drug-resistant. Reduce costs
...PRESENTATIONS... Guidelines for the Management of Community-Acquired Pneumonia Richard E. Chaisson, MD Presentation Summary Guidelines for the treatment of community-acquired pneumonia (CAP) have been
More informationORIGINAL INVESTIGATION. Associations Between Initial Antimicrobial Therapy and Medical Outcomes for Hospitalized Elderly Patients With Pneumonia
ORIGINAL INVESTIGATION Associations Between Initial Antimicrobial Therapy and Medical Outcomes for Hospitalized Elderly Patients With Pneumonia Patrick P. Gleason, PharmD; Thomas P. Meehan, MD, MPH; Jonathan
More informationAntibiotics Use And Concordance To Guidelines For Patients Hospitalized With Community Acquired Pneumonia (CAP)
Antibiotics Use And Concordance To Guidelines For Patients Hospitalized With Community Acquired Pneumonia (CAP) SF Teoh 1, Samsinah Hussain 1, CK Liam 2 1 Departments of Pharmacy, Faculty of Medicine,
More informationESISTONO LE HCAP? Francesco Blasi. Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano
ESISTONO LE HCAP? Francesco Blasi Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano Community-acquired pneumonia (CAP): Management issues
More informationAntibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia A Systematic Review
Clinical Review & Education Review Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia A Systematic Review Jonathan S. Lee, MD; Daniel L. Giesler, MD, PharmD; Walid F. Gellad,
More informationPneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center
Pneumonia considerations 2017 Galia Rahav Infectious diseases unit Sheba medical center Sir William Osler (1849 1919) "Father of modern medicine Pneumonia: The old man's friend The captain of the men of
More informationCommunity-Acquired Pneumonia. Community-Acquired Pneumonia. Community Acquired Pneumonia (CAP): definition
Community-Acquired Pneumonia Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital Community-Acquired Pneumonia Talk will focus on adults Guideline for healthy infants
More informationPneumonia. Community Acquired Pneumonia (CAP): definition. At least 2 new symptoms
Pneumonia Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital Community Acquired Pneumonia (CAP): definition At least 2 new symptoms Fever or hypothermia Cough Rigors
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationIMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP)
IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,
More informationMeasure Information Form
Release Notes: Measure Information Form Version 2.0 Measure Information Form Measure Set: Pneumonia (PN) Set Measure ID #: Organization Set Measure ID# Time Intervals JCHO 0-8 hours CMS/JCHO 0-4 hours
More informationMeasure Information Form Collected For: CMS Voluntary Only The Joint Commission - Retired
Measure Information Form Collected For: CMS Voluntary Only The Joint Commission - Retired Last Updated: Version 4.3a Measure Set: Pneumonia (PN) Set Measure I #: Performance Measure Name: lood Cultures
More informationBai-Yi Chen MD. FCCP
Treatment strategies for hospitalized versus nonhospitalized CAP patients: Asian perspective Bai-Yi Chen MD. FCCP Professor of Medicine Division of Infectious Disease, Infection Control Team The First
More informationHealthcare-Associated Pneumonia in the Emergency Department
Healthcare-Associated Pneumonia in the Emergency Department Ellen M. Slaven, M.D., 1 Jairo I. Santanilla, M.D., 1,2 and Peter M. DeBlieux, M.D. 1 ABSTRACT Emergency medicine clinicians frequently diagnose
More informationTiming of antibiotic administration and outcomes of hospitalized patients with community-acquired and healthcare-associated pneumonia
ORIGINAL ARTICLE INFECTIOUS DISEASES Timing of antibiotic administration and outcomes of hospitalized patients with community-acquired and healthcare-associated pneumonia A. Simonetti 1, D. Viasus 1, C.
More informationORIGINAL INVESTIGATION. Antibiotic Therapy for Ambulatory Patients With Community-Acquired Pneumonia in an Emergency Department Setting
Antibiotic Therapy for Ambulatory Patients With Community-Acquired Pneumonia in an Emergency Department Setting Christine Malcolm, BSc; Thomas J. Marrie, MD ORIGINAL INVESTIGATION Background: Little attention
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationCombination vs Monotherapy for Gram Negative Septic Shock
Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham
More informationResearch & Reviews: Journal of Hospital and Clinical Pharmacy
Research & Reviews: Journal of Hospital and Clinical Pharmacy Empiric Antibiotic Prescribing For Community Acquired Pneumonia and Patient Characteristics Associated with Broad Spectrum Antibiotic Use Mirza
More informationClinical Policy for the Management and Risk Stratification of Community-Acquired Pneumonia in Adults in the Emergency Department
Clinical Policy for the Management and Risk Stratification of Community-Acquired Pneumonia in Adults in the Emergency Department This clinical policy was developed by the ACEP Clinical Policies Committee
More informationPeriod of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationCompliance with antibiotic treatment guidelines in managed care patients with communityacquired pneumonia in ambulatory settings
Compliance with antibiotic treatment guidelines in managed care patients with communityacquired pneumonia in ambulatory settings Jasmanda H. Wu, Ph.D., 1 David H. Howard, Ph.D., 2 John E. McGowan, Jr.,
More informationTreatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days
Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Executive Summary National consensus guidelines created jointly by the Infectious Diseases Society of
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationObjectives 4/26/2017. Co-Investigators Sadie Giuliani, PharmD, BCPS Claude Tonnerre, MD Jayme Hartzell, PharmD, MS, BCPS
IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,
More informationCommunity Acquired Pneumonia. Epidemiology: Acute Lower Respiratory Tract Infections. Community Acquired Pneumonia (CAP) Outline
Community Acquired Pneumonia (CAP) Outline Lisa G. Winston, MD University of California, San Francisco Zuckerberg San Francisco General Epidemiology Diagnosis Microbiology Risk stratification Treatment
More informationCLINICAL PROTOCOL FOR COMMUNITY ACQUIRED PNEUMONIA. SCOPE: Western Australia. CORB score equal or above 1. All criteria must be met:
CLINICAL PROTOCOL F COMMUNITY ACQUIRED PNEUMONIA SCOPE: Western Australia All criteria must be met: Inclusion Criteria Exclusion Criteria CB score equal or above 1. Mild/moderate pneumonia confirmed by
More informationAntibiotic Prescription Patterns in Hospitalized Patients with Nursing Home acquired Pneumonia
ORIGINAL RESEARCH Antibiotic Prescription Patterns in Hospitalized Patients with Nursing Home acquired Pneumonia Ali A. El-Solh, MD, MPH 1,2,3 Misha Peter, MD 1 Ziad Alfarah, MD 1 Morohunfolu. E. Akinnusi,
More informationPneumococcal urinary antigen test use in diagnosis and treatment of pneumonia in seven Utah hospitals
ORIGINAL ARTICLE PNEUMONIA Pneumococcal urinary antigen test use in diagnosis and treatment of pneumonia in seven Utah hospitals Devin M. West 1, Lindsay M. McCauley 2,3, Jeffrey S. Sorensen 2, Al R. Jephson
More informationCommunity-Acquired Pneumonia. Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital. Nothing to disclose.
Community-Acquired Pneumonia Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital Nothing to disclose. Community-Acquired Pneumonia Talk will focus on adults Guideline
More informationCommunity-acquired pneumonia (CAP) is a common,
OUTCOMES IN PRACTICE A Tool for Appropriate Antibiotic Use in the Management of Community-Acquired Pneumonia Alan B. Bernstein, MD, MPH, Thomas M. File Jr, MD, and Jeffrey S. Markowitz, DrPH Community-acquired
More informationSuitability of Antibiotic Treatment for CAP (CAPTIME) The duration of antibiotic treatment in community acquired pneumonia (CAP)
STUDY PROTOCOL Suitability of Antibiotic Treatment for CAP (CAPTIME) Purpose The duration of antibiotic treatment in community acquired pneumonia (CAP) lasts about 9 10 days, and is determined empirically.
More informationTreatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance
Journal of Antimicrobial Chemotherapy (2008) 61, 1162 1168 doi:10.1093/jac/dkn073 Advance Access publication 29 February 2008 Treatment costs associated with community-acquired pneumonia by community level
More informationSeven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia a propensity-adjusted analysis
ORIGINAL ARTICLE INFECTIOUS DISEASES Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia a propensity-adjusted analysis G. Choudhury, P. Mandal,
More informationSafety and efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia
Journal of Antimicrobial Chemotherapy Advance Access published November 16, 2010 J Antimicrob Chemother doi:10.1093/jac/dkq426 Safety and efficacy of CURB65-guided antibiotic therapy in community-acquired
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationMethicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship
Methicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship Natalie R. Tucker, PharmD Antimicrobial Stewardship Pharmacist Tyson E. Dietrich, PharmD PGY2 Infectious Diseases
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Community Acquired 1) Is it pneumonia? ie new symptoms and signs of a lower respiratory
More informationHoward Friedman, PhD, 1 Xue Song, PhD, 2 Simone Crespi, MPH, 3 Prakash Navaratnam, MPH, PhD 4. Introduction
Volume 12 Number 8 2009 VALUE IN HEALTH Comparative Analysis of Length of Stay,Total Costs, and Treatment Success between Intravenous 400 mg and 750 mg among Hospitalized Patients with Community-Acquired
More informationIDSA GUIDELINES COMMUNITY ACQUIRED PNEUMONIA
page 1 / 5 page 2 / 5 idsa guidelines community acquired pdf IDSA/ATS Guidelines for CAP in Adults CID 2007:44 (Suppl 2) S29 such as blood and sputum cultures. Conversely, these cultures may have a major
More informationPneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC
Pneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC APPROVED BY: Policy and Guidelines Committee TRUST REFERENCE: B9/2009 AWP Ref: AWP61 Date (approved): July 2008 REVIEW
More informationAdherence to guidelines empirical antibiotic recommendations and community-acquired pneumonia outcome
Eur Respir J 2008; 32: 892 901 DOI: 10.1183/09031936.00163407 CopyrightßERS Journals Ltd 2008 Adherence to guidelines empirical antibiotic recommendations and community-acquired pneumonia outcome P.G.
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Pneumonia Community Acquired Pneumonia 1) Is it pneumonia? ie new symptoms and signs of
More informationUse of Indicators to Evaluate the Quality of Community-Acquired Pneumonia Management
MAJOR ARTICLE Use of Indicators to Evaluate the Quality of Community-Acquired Pneumonia Management Dilip Nathwani, 1 Fiona Williams, 3 John Winter, 2 Janet Winter, 2 Simon Ogston, 3 and Peter Davey 1 1
More informationCommunity-Acquired Pneumonia: Severity scoring and compliance to BTS guidelines. Julie Harris Antibiotic Pharmacist Hywel Dda Healthboard
Community-Acquired Pneumonia: Severity scoring and compliance to BTS guidelines Julie Harris Antibiotic Pharmacist Hywel Dda Healthboard Plan Background BTS guidelines Differences in opinion Measures introduced
More informationCommunity Acquired Pneumonia: An Update on Guidelines
Community Acquired Pneumonia: An Update on Guidelines Claudia Summa, BScPhm Pharmacy Resident September 12, 2006 Objectives To give a brief description of the pathophysiology of community acquired pneumonia
More informationAntibiotic Choice And Patient Outcomes In Community-Acquired Pneumonia
Antibiotic Choice And Patient Outcomes In Community-Acquired Pneumonia William]. Hueston, MD, andmarlaa. Schiafflno, MD Bacllgrountl: We investigated whether any clinical or nonclinical variables were
More informationCommunity-acquired pneumonia: Time to place a CAP on length of treatment?
LOGIN TO LEARN: An Engaging and Interactive Journal Club for Pharmacists and Students Community-acquired pneumonia: Time to place a CAP on length of treatment? Jennifer Ball, PharmD Learning Objectives
More informationDuke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients
Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients PURPOSE Fever among neutropenic patients is common and a significant cause of morbidity
More informationMore than 4 million episodes of communityacquired
Overview of Recent Guidelines for the Management of Community-Acquired Pneumonia David C. Rhew, MD More than 4 million episodes of communityacquired pneumonia (CAP) occur each year in the United States,
More informationEpidemiology of early-onset bloodstream infection and implications for treatment
Epidemiology of early-onset bloodstream infection and implications for treatment Richard S. Johannes, MD, MS Marlborough, Massachusetts Health care-associated infections: For over 35 years, infections
More informationDoes Early and Appropriate Antibiotic Administration Improve Mortality in Emergency Department Patients with Severe Sepsis or Septic Shock?
References and Literature Grading Does Early and Appropriate Antibiotic Administration Improve Mortality in Emergency Department Patients with Severe Sepsis or Septic Shock? (9/6/2015) 1. Dellinger, R.P.,
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationActive Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply.
Impact of routine surgical ward and intensive care unit admission surveillance cultures on hospital-wide nosocomial methicillin-resistant Staphylococcus aureus infections in a university hospital: an interrupted
More informationImpact of Blood Cultures on the Changes of Treatment in Hospitalized Patients with Community-Acquired Pneumonia
Send Orders of Reprints at reprints@benthamscience.net 60 The Open Respiratory Medicine Journal, 2013, 7, 60-66 Impact of Blood Cultures on the Changes of Treatment in Hospitalized Patients with Community-Acquired
More informationHospital-acquired pneumonia (HAP) is the second
Guidelines and Critical Pathways for Severe Hospital-Acquired Pneumonia* Stanley Fiel, MD, FCCP Hospital-acquired pneumonia (HAP) is associated with high morbidity and mortality. Early, appropriate, and
More informationMAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges
Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control
More informationAntibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco
Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance
More informationHealthcare-associated Infections and Antimicrobial Use Prevalence Survey
Healthcare-associated Infections and Antimicrobial Use Prevalence Survey Shamima Sharmin, M.B.B.S., MSc, MPH Emerging Infections Program New Mexico Department of Health Agenda Recognize healthcare-associated
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationORIGINAL INVESTIGATION. Doxycycline Is a Cost-effective Therapy for Hospitalized Patients With Community-Acquired Pneumonia
ORIGINAL INVESTIGATION Doxycycline Is a Cost-effective Therapy for Hospitalized Patients With Community-Acquired Pneumonia Reba K. Ailani, MD; Gautami Agastya, MD; Rajesh K. Ailani, MD; Beejadi N. Mukunda,
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationOutcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance Joshua P. Metlay 1 and Daniel E.
Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance Joshua P. Metlay 1 and Daniel E. Singer 2 1 Veterans Affairs Medical Center and Division of General Internal
More informationThe Three R s Rethink..Reduce..Rocephin
The Three R s Rethink..Reduce..Rocephin By: Alisa Cuff RN,BN,CIC and John Bautista B.Sc. (Chem), B.Sc.Pharm, M.Sc.Pharm IPAC National Conference 2017 Newfoundland and Labrador Regional Health Authorities
More informationSafety of an Out-Patient Intravenous Antibiotics Programme
Safety of an Out-Patient Intravenous Antibiotics Programme Chan VL, Tang ESK, Leung WS, Wong L, Cheung PS, Chu CM Department of Medicine & Geriatrics United Christian Hospital Outpatient Parental Antimicrobial
More informationChallenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S.
Challenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S. Overview of benchmarking Antibiotic Use Scott Fridkin, MD, Senior Advisor for Antimicrobial
More informationSHC Clinical Pathway: HAP/VAP Flowchart
SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationA clinical pathway for community-acquired pneumonia: an observational cohort study
RESEARCH ARTICLE A clinical pathway for community-acquired pneumonia: an observational cohort study Open Access Christopher R Frei 1,2*, Allison M Bell 1,2, Kristi A Traugott 1,2,3, Terry C Jaso 1,4, Kelly
More informationOptimize Durations of Antimicrobial Therapy
Optimize Durations of Antimicrobial Therapy Evidence & Application Jill Cowper, Pharm.D. Division Infectious Diseases Pharmacist Parallon Supply Chain Solutions Richmond, VA P: 607 221 5101 jill.butterfield@parallon.com
More informationUCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients
Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management
More informationNewsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017
Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017 Newsflash: Fluoroquinolones Newsflash: Fluoroquinolones Don t
More informationStreptococcus pneumoniae Bacteremia: Duration of Previous Antibiotic Use and Association with Penicillin Resistance
MAJOR ARTICLE Streptococcus pneumoniae Bacteremia: Duration of Previous Antibiotic Use and Association with Penicillin Resistance Jörg J. Ruhe and Rodrigo Hasbun Department of Medicine, Infectious Diseases
More informationPOINT PREVALENCE SURVEY A tool for antibiotic stewardship in hospitals. Koen Magerman Working group Hospital Medicine
POINT PREVALENCE SURVEY A tool for antibiotic stewardship in hospitals Koen Magerman Working group Hospital Medicine Background Strategic plan By means of a point prevalence survey and internal audits
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationORIGINAL INVESTIGATION. Increasing Outpatient Fluoroquinolone Exposure Before Tuberculosis Diagnosis and Impact on Culture-Negative Disease
ORIGINAL INVESTIGATION Increasing Outpatient Fluoroquinolone Exposure Before Tuberculosis Diagnosis and Impact on Culture-Negative Disease Pinky D. Gaba, MD; Connie Haley, MD, MPH; Marie R. Griffin, MD,
More informationFollow this and additional works at:
University of Massachusetts Amherst ScholarWorks@UMass Amherst Masters Theses Dissertations and Theses 2014 Penicillin Use and Duration of Bacteremia, Length of Stay, and 30-day Readmission in Hospitalized
More informationLack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization
Infect Dis Ther (2014) 3:55 59 DOI 10.1007/s40121-014-0028-8 BRIEF REPORT Lack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization
More informationSource: Portland State University Population Research Center (
Methicillin Resistant Staphylococcus aureus (MRSA) Surveillance Report 2010 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Health Authority Updated:
More informationSystematic Review of Clinical PK-PD Studies of Antibacterials. Alex McAleenan Julian Higgins Alasdair MacGowan William Hope Johan Mouton
Systematic Review of Clinical PK-PD Studies of Antibacterials Alex McAleenan Julian Higgins Alasdair MacGowan William Hope Johan Mouton Background It has been suggested that there are problems with current
More informationBarriers to Intravenous Penicillin Use for Treatment of Nonmeningitis
JCM Accepts, published online ahead of print on 7 July 2010 J. Clin. Microbiol. doi:10.1128/jcm.01012-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationSuccessful stewardship in hospital settings
Successful stewardship in hospital settings Pr Charles-Edouard Luyt Service de Réanimation Institut de Cardiologie Groupe Hospitalier Pitié-Salpêtrière Université Pierre et Marie Curie, Paris 6 www.reamedpitie.com
More informationAND MISCONCEPTIONS IN THE MANAGEMENT OF SEPSIS
MYTHS AND MISCONCEPTIONS IN THE MANAGEMENT OF SEPSIS SEPSISMADE EASY SURVIVINGSEPSIS COOKBOOK SEPSIS ISAPIE MERVYN SINGER BLOOMSBURY INSTITUTE OF INTENSIVE CARE MEDICINE UNIVERSITY COLLEGE LONDON, UK DISCUSSION
More informationIs Cefazolin Inferior to Nafcillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia?
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2011, p. 5122 5126 Vol. 55, No. 11 0066-4804/11/$12.00 doi:10.1128/aac.00485-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Is Cefazolin
More informationReceived: Accepted: Access this article online Website: Quick Response Code:
Indian Journal of Drugs, 2016, 4(3), 69-74 ISSN: 2348-1684 STUDY ON UTILIZATION PATTERN OF ANTIBIOTICS AT A PRIVATE CORPORATE HOSPITAL B. Chitra Department of Pharmacy Practice, College of Pharmacy, Sri
More informationInfectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles
Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Conflicts of Interest None at this time May be discussing off-label indications KALIN M. CLIFFORD, PHARM.D., BCPS,
More informationAntimicrobial treatment of community acquired pneumonia in adults: A conference report
CONSENSUS CONFERENCE Antimicrobial treatment of community acquired pneumonia in adults: A conference report THE CANADIAN COMMUNITY ACQUIRED PNEUMONIA CONSENSUS CONFERENCE GROUP C OMMUNLTY ACQUIRED PNEUMONI
More informationAlgorithm To Determine Cost Savings of Targeting Antimicrobial Therapy Based on Results of Rapid Diagnostic Testing
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 2003, p. 4708 4713 Vol. 41, No. 10 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.10.4708 4713.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationA year in review in community-acquired respiratory tract infections
A year in review in community-acquired respiratory tract infections Paul M. Tulkens, MD, PhD * Cellular and Molecular Pharmacology & Center for Clinical Pharmacy Louvain Drug Research Institute, Catholic
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationAntimicrobial Prescribing for Upper Respiratory Infections and Its Effect on Return Visits
182 March 2009 Family Medicine Clinical Research and Methods Antimicrobial Prescribing for Upper Respiratory Infections and Its Effect on Return Visits John Li, MPH; Anindya De, PhD; Kathy Ketchum, RPh,
More information